Drag a card by its title · ⚙ to size, swap or remove

The company

Enliven Therapeutics, Inc.

ELVN · Nasdaq

Health CareBiotechnologyNot moving yet

ELVN stood above a rising 150-day average in 43 of the last 52 weekly readings, and has been out of that trend for the last 2 weeks. It is 20.2% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 2
Industry in uptrend: 15% -17 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $151.6M
Officials’ trades on record: 0
Institutions holding: 204 (+45)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 43 of 52 weeks.

17 Apr – 16 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0

Sale orders, 12 months37

Buyers · sellers0 · 10

Who	Did	Shares	Traded
J. Scott GarlandDirector	sold	13,000at $46.67	1 Oct 2026filed 5 Oct 2026
Helen Louise CollinsCHIEF MEDICAL OFFICER	sold	2,916at $50.03	17 Sep 2026filed 21 Sep 2026
Helen Louise CollinsCHIEF MEDICAL OFFICER	sold	1,844at $50.71	17 Sep 2026filed 21 Sep 2026
Helen Louise CollinsCHIEF MEDICAL OFFICER	sold	240at $51.48	17 Sep 2026filed 21 Sep 2026
Benjamin HohlCHIEF FINANCIAL OFFICER	sold	3,535at $50.03	17 Sep 2026filed 21 Sep 2026
Benjamin HohlCHIEF FINANCIAL OFFICER	sold	2,194at $50.72	17 Sep 2026filed 21 Sep 2026
Benjamin HohlCHIEF FINANCIAL OFFICER	sold	289at $51.49	17 Sep 2026filed 21 Sep 2026
Helen Louise CollinsCHIEF MEDICAL OFFICER	sold	3,900at $58.37	17 Aug 2026filed 19 Aug 2026
Helen Louise CollinsCHIEF MEDICAL OFFICER	sold	1,100at $59.35	17 Aug 2026filed 19 Aug 2026
Benjamin HohlCHIEF FINANCIAL OFFICER	sold	4,630at $58.35	17 Aug 2026filed 19 Aug 2026
Benjamin HohlCHIEF FINANCIAL OFFICER	sold	1,388at $59.35	17 Aug 2026filed 19 Aug 2026
Mika K. DerynckDirector	sold	158,795at $60.21	4 Aug 2026filed 6 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders204+45 on the quarter

New · exited67 · 21

Reported value$3.9B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
FMR LLCadded · filed 13 Aug 2026	10,025,017$508.8M	+3,195,771+46.8%
ORBIMED ADVISORS LLCreduced · filed 14 Aug 2026	6,776,632$343.9M	-1,182,906−14.9%
Polar Capital Holdings Plcadded · filed 14 Aug 2026	6,430,636$326.4M	+1,364,703+26.9%
BlackRock, Inc.added · filed 7 Aug 2026	4,359,704$221.3M	+674,997+18.3%
Vestal Point Capital, LPadded · filed 14 Aug 2026	4,000,000$203.0M	+750,000+23.1%
Commodore Capital LPunchanged · filed 14 Aug 2026	3,275,000$166.2M	00.0%
VANGUARD CAPITAL MANAGEMENT LLCnew · filed 13 Aug 2026	2,569,002$130.4M	+2,569,002
CITADEL ADVISORS LLCadded · filed 14 Aug 2026	2,068,992$105.0M	+325,077+18.6%
Fairmount Funds Management LLCunchanged · filed 14 Aug 2026	1,855,644$94.2M	00.0%
Siren, L.L.C.added · filed 13 Aug 2026	1,774,411$90.1M	+1,028,185+137.8%